

Gonadotropin Releasing Hormone Analogs (GnRH)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	Varies upon diagnosis

Medications	Quantity Limit	Comment
Camcevi (leuprolide mesylate) 42mg kit	1 per 24 weeks	N/A
Eligard (leuprolide acetate) 7.5mg	1 per 4 weeks	N/A
Eligard (leuprolide acetate) 22.5mg	1 per 12 weeks	N/A
Eligard (leuprolide acetate) 30mg	1 per 16 weeks	N/A
Eligard (leuprolide acetate) 45mg	1 per 24 weeks	N/A
Fensolvi (leuprolide acetate) 45mg kit	1 per 24 weeks	N/A
Firmagon (degarelix)80mg	1 injection (80 mg) per 28 days	N/A
Firmagon (degarelix) 120mg	2 injections (240 mg) per year	N/A
Lupaneta Pack (leuprolide acetate and norethindrone) 3.75 mg/5 mg	1 per 4 weeks	N/A
Lupaneta Pack (leuprolide acetate and norethindrone) 11.25 mg/5 mg	1 per 12 weeks	N/A
Leuprolide acetate (immediate release)	N/A	N/A
Lupron Depot (1 month) (leuprolide acetate) 3.75mg	1 per 4 weeks	***See note below
Lupron Depot (1 month) (leuprolide acetate) 7.5mg	1 per 4 weeks	***See note below
Lupron Depot (3 month) (leuprolide acetate) 11.25mg and 22.5mg	1 per 12 weeks	***See note below
Lupron Depot (4 month) (leuprolide acetate) 30mg	1 per 16 weeks	***See note below
Lupron Depot (6 month) (leuprolide acetate) 45mg	1 per 24 weeks	***See note below
Lupron Depot Ped (leuprolide acetate) 7.5mg	1 per 4 weeks	***See note below
Lupron Depot Ped (leuprolide acetate) 11.25mg	1 per 4 weeks	***See note below
Lupron Depot Ped (leuprolide acetate) 15mg	1 per 4 weeks	***See note below

Lupron Depot Ped (3 month) (leuprolide acetate) 11.25mg	1 per 12 weeks	***See note below
Lupron Depot Ped (3 month) (leuprolide acetate) 30mg	1 per 12 weeks	***See note below
Lupron Depot Ped (6 month) (leuprolide acetate) 45mg	1 per 24 weeks	***See note below
Supprelin LA (histrelin acetate) 50mg Implant	1 per year	N/A
Synarel Nasal Spray (nafarelin acetate)	5 bottles per 30 days	N/A
Trelstar (triptorelin pamoate) 22.5mg	1 per 24 weeks	N/A
Trelstar Depot (triptorelin pamoate) 3.75mg	1 per 4 weeks	N/A
Trelstar LA (triptorelin pamoate) 11.25mg	1 per 12 weeks	N/A
Triptodur (triptorelin pamoate extended release) 22.5mg kit	1 kit per 24 weeks	N/A
Vantas (histrelin acetate) 50mg Implant	1 per year	N/A
Zoladex (1 month) (goserelin acetate) 3.6mg Implant	1 per 4 weeks	N/A
Zoladex (3 month) (goserelin acetate) 10.8mg Implant	1 per 12 weeks	N/A

*****Note: For Eligard, Leuprolide acetate (immediate release) or Lupron Depot request for infertility please see the separate clinical criteria document (Infertility Clinical Criteria) detailing that specific approval criteria**

APPROVAL CRITERIA

- I. **Breast Cancer – goserelin acetate (Zoladex), leuprolide acetate (Lupron Depot), or triptorelin pamoate (Trelstar)**
 - A. Goserelin acetate (Zoladex), leuprolide acetate (Lupron Depot) or triptorelin pamoate (Trelstar) may be approved for the treatment of men and pre- or perimenopausal women with hormone receptor positive breast cancer (Trelstar – Pagani, 2014).
 - B. Leuprolide acetate (Lupron, Lupron Depot) may not be approved for individuals premenopausal and diagnosed with non-invasive ductal carcinoma in situ (DCIS) of the breast.
- II. **Ovarian Cancer (including fallopian tube cancer and primary peritoneal cancer) – leuprolide acetate (Lupron Depot)**

Leuprolide acetate (Lupron Depot) may be approved for ovarian cancer if the following are met:

- A. Hormonal therapy for clinical relapse in individuals with stage II-IV granulosa cell tumors; **OR**
- B. Hormonal therapy for treatment of epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer as a single agent for persistent disease or recurrence.

III. **Prostate Cancer - degarelix (Firmagon), goserelin acetate (Zoladex), histrelin acetate (Vantas), leuprolide acetate (Eligard, Lupron Depot), leuprolide acetate (immediate release), leuprolide mesylate (Camcevi), or triptorelin pamoate (Trelstar)**

A. Degarelix (Firmagon), goserelin acetate (Zoladex), histrelin acetate (Vantas), leuprolide acetate (Eligard, Lupron Depot), leuprolide (immediate release), leuprolide mesylate (Camcevi), or triptorelin pamoate (Trelstar) may be approved for the treatment of prostate cancer if any of the following indications are met:

1. Used as androgen deprivation therapy as a single agent or in combination with an antiandrogen; **OR**
2. Used for clinically localized disease* with intermediate (T2b to T2c cancer, Gleason score of 7/Gleason grade group 2-3, or prostate specific antigen (PSA) value of 10-20 ng/ml) or higher risk of recurrence as neoadjuvant therapy with radiation therapy or cryosurgery; **OR**
3. Used for progressive castration-naïve disease; **OR**
4. Used for castration-recurrent disease; **OR**
5. Other advanced*, recurrent, or metastatic disease*.

*Definitions:

- Clinically localized prostate cancer: Cancer presumed to be confined within the prostate based on pre-treatment findings such as physical exam, imaging, and biopsy findings.
- Locally advanced disease (prostate cancer): Cancer that has spread from where it started to nearby tissue or lymph nodes.
- Metastatic: The spread of cancer from one part of the body to another; a metastatic tumor contains cells that are like those in the original (primary) tumor and have spread.
- Advanced prostate cancer: Disease that has spread beyond the prostate to surrounding tissues or distant organs.

IV. **Central Precocious Puberty - leuprolide acetate (Fensolvi, Lupron Depot-Ped), nafarelin acetate (Synarel Nasal Spray), histrelin acetate subcutaneous implant (Supprelin LA, Vantas), or triptorelin pamoate intramuscular extended release (Triptodur)**

- A. Leuprolide acetate (Fensolvi, Lupron Depot-Ped), nafarelin acetate (Synarel Nasal Spray), histrelin acetate subcutaneous implant (Supprelin LA, Vantas), and triptorelin pamoate (Triptodur) may be approved for individuals 14 years of age or younger (Kaplowitz, et al. 2016); **AND**
- B. Documentation is provided that individual has a diagnosis of central precocious puberty (defined as the beginning of secondary sexual characteristics before age 8 in girls and 9 in boys) (Kaplowitz, et al. 2016); **AND**
- C. Documentation is provided that the diagnosis of CPP has been confirmed by one of the following:
 - i. A pubertal response to a gonadotropin hormone (GnRH) agonist test; **OR**

- ii. A pubertal level of a third generation luteinizing hormone (LH) assay; **OR**
- iii. A pubertal level of a pediatric luteinizing hormone (LH) assay; **OR**
- iv. A pubertal level of an ultra-sensitive luteinizing hormone (LH) assay; **OR**
- v. A pubertal level on a luteinizing hormone (LH) assay that can detect levels less than 0.2; **AND**

D. The diagnosis has been confirmed by assessment of bone age versus chronological age.

Requests for Leuprolide acetate (Fensolvi, Lupron Depot-Ped), nafarelin acetate (Synarel Nasal Spray), histrelin acetate subcutaneous implant (Supprelin LA, Vantas), or triptorelin pamoate intramuscular extended release (Triptodur) may not be approved if the following criteria are met:

- A. Individual is diagnosed with peripheral precocious puberty; **OR**
- B. Individual is diagnosed with benign or non-progressive precocious puberty.

V. **Gynecology Uses - goserelin acetate (Zoladex), leuprolide acetate (Lupron Depot, Lupron Depot-Ped), leuprolide acetate for depot suspension and norethindrone (Lupaneta Pack), or nafarelin acetate (Synarel Nasal Spray)**

A. Goserelin acetate (Zoladex), leuprolide acetate (Lupron Depot, Lupron Depot-Ped), or nafarelin acetate (Synarel Nasal Spray) may be approved if the following criteria are met:

- 1. Individual has a diagnosis of chronic pelvic pain (defined as “pain symptoms perceived to originate from pelvic organs or structures typically lasting more than six months...with symptoms suggestive of lower urinary tract, sexual, bowel, pelvic floor, myofascial, or gynecological dysfunction”) [ACOG, 2020]) (Initial authorization for chronic pelvic pain: 3 months); **OR**
- 2. Individual is using to induce amenorrhea (including, but not limited to menstruating women diagnosed with severe thrombocytopenia or aplastic anemia).

Continuation requests for Chronic Pelvic Pain may **be** approved if the individual has confirmation of symptomatic relief. (Reauthorization for chronic pelvic pain: 3 months).

Continuation requests for Chronic Pelvic Pain may **not** be approved if the individual has no symptomatic relief.

OR

B. Goserelin acetate (Zoladex) may be approved if the following criteria are met:

- 1. Individual is using for treatment of endometriosis and duration of treatment limited to 6 months; **OR**
- 2. Individual is using for dysfunctional uterine bleeding; **OR**

3. Individual is using for endometrial thinning prior to endometrial ablation for dysfunctional uterine bleeding (3.6 mg implant only).

C. Leuprolide acetate (Lupron Depot, Lupron Depot-Ped) may be approved if the following criteria are met:

1. Individual is using for initial treatment or retreatment of endometriosis (Initial treatment duration: 6 months; Retreatment duration: a single course for 6 months. Total duration of therapy should not exceed 12 months); **OR**
2. Individual is using for preoperative treatment as adjunct to surgical treatment of uterine fibroids (leiomyoma uteri), including but not limited to reducing the size of fibroids to allow for a vaginal procedure (AHFS); **OR**
3. Individual is using prior to surgical treatment (myomectomy or hysterectomy) in those with a diagnosis of confirmed anemia (Letheby et.al. 2001, 2017); **OR**
4. Individual is using for endometrial thinning prior to endometrial ablation for dysfunctional uterine bleeding.

D. Leuprolide acetate for depot suspension and norethindrone acetate tablets (Lupaneta Pack) may be approved if the following criteria are met:

1. Individual is using for initial treatment or retreatment of endometriosis (Initial treatment duration: 6 months; Retreatment duration: a single course for 6 months. Total duration of therapy should not exceed 12 months).

E. Nafarelin acetate (Synarel Nasal Spray) may be approved the following criteria are met:

1. Individual is using for endometriosis; **AND**
2. Duration of treatment limited to 6 months.

VI. Ovarian Preservation for Fertility during Chemotherapy or Radiation - leuprolide acetate (Eligard, Lupron Depot), leuprolide acetate (immediate release), degarelix (Firmagon), triptorelin pamoate (Trelstar), histrelin acetate implant (Vantas), goserelin acetate (Zoladex)

A. Leuprolide acetate (Eligard, Lupron Depot), leuprolide acetate (immediate release), degarelix (Firmagon), triptorelin pamoate (Trelstar), histrelin acetate implant (Vantas), Goserelin acetate (Zoladex) may be approved if the following criteria are met:

1. Individual is using in the preservation of fertility in pre-menopausal women; **AND**
2. Individual currently has a cancer diagnosis; **AND**
3. Individual meets one of the following:
 - a. Individual will receive chemotherapy for cancer with a curative intent; **OR**
 - b. Individual will receive radiation for cancer with a curative intent.

VII. Gender Dysphoria/Incongruence

A. Requests for all GnRH analogs - Zoladex (goserelin acetate), Vantas or Supprelin LA (histrelin acetate), Fensolvi or Lupron Depot or Lupron Depot-Ped, (leuprolide acetate), Lupaneta Pack (leuprolide acetate for depot suspension and norethindrone acetate tablets), Synarel Nasal Spray (nafarelin acetate), or Triptodur (triptorelin pamoate) may be approved if the following criteria are met:

1. Individual has a diagnosis of gender dysphoria/incongruence (Coleman 2022); **AND**
2. Individual has experienced puberty to at least Tanner stage 2 (Hembree 2017, Coleman 2022).

VIII. Salivary Gland Tumors – leuprolide acetate (Eligard, Lupron Depot)

A. Leuprolide acetate (Eligard, Lupron Depot) may be approved for the treatment of salivary gland tumors if the following criteria are met (NCCN 2A):

1. Individual has androgen receptor positive recurrent disease with distant metastases; **AND**
2. Individual has a current Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-3.

Key References:

1. Balbi G, Piano LD, Cardone A, Cirelli G. Second-line therapy of advanced ovarian cancer with GnRH analogs. *Int J Gynecol Cancer*. 2004; 14(5):799-803.
2. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2020. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
3. Dalin MG, Watson PA, Ho AL, Morris LG. Androgen receptor signaling in salivary gland cancer. *Cancers*. 2017; 9(2)pii:E17.
4. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: October 12, 2020.
5. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
6. Elgindy EA, El-Haieg DO, Khorshid OM, et al. Gonadotrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial. *Obstet Gynecol*. 2013; 121(1):78-86.
7. Fishman A, Kudelka AP, Tresukosol D, et al. Leuprolide acetate for treating refractory or persistent ovarian granulosa cell tumor. *J Reprod Med*. 1996; 41(6):393-396.
8. Fushimi C, Tada Y, Takahashi H, et al. A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma. *Ann Oncol*. 2017 Dec 1; [Epub ahead of print]. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29211833>. Accessed on October 12, 2020.
9. Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. *Ann Intern Med*. 2002; 137(8):678-687.
10. Hotko YS. Male breast cancer: clinical presentation, diagnosis, treatment. *Exp Oncol*. 2013; 35(4):303-310.
11. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2020; Updated periodically.
12. NCCN Clinical Practice Guidelines in Oncology™. © 2019 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on October 12, 2020.
 - Breast Cancer. V6.2020. Revised September 8, 2020.
 - Head and Neck Cancers. V2.2020. Revised June 9, 2020.
 - Ovarian Cancer. V1.2020. Revised March 11, 2020.
 - Prostate Cancer. V1.2022. Revised September 10, 2021.
13. Pagani O, Regan MM, Walley BA, et al.; TEXT and SOFT Investigators; International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. *N Engl J Med*. 2014; 371(2):107-118.
14. Rao GG, Miller DS. Hormonal therapy in epithelial ovarian cancer. *Expert RevAnticancer Ther*. 2006; 6(1):43-47.
15. Sverrisdottir A, Nystedt M, Johansson H, Fornander T. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. *Breast Cancer Res Treat*. 2009; 117(3):561-570.

16. Wilt TJ, MacDonald R, Rutks I, et al. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. *Ann Intern Med.* 2008; 148(6):435-448.
17. Yokoyama Y, Mizunuma H. Recurrent epithelial ovarian cancer and hormone therapy. *World J Clin Cases.* 2013; 1(6):187-190.
18. American College of Obstetrics and Gynecology Committee on Practice Bulletins -- Gynecology. ACOG Practice Bulletin No. 51. Chronic pelvic pain. *Obstet Gynecol.* 2004 (reaffirmed 2008); 103(3):589-605.
19. American College of Obstetricians and Gynecologists. reVitalize. Gynecology data definitions (version 1.0). Washington, DC: American College of Obstetricians and Gynecologists; 2018. Available at: <https://www.acog.org/-/media/Departments/Patient-Safety-and-Quality-Improvement/reVITALize-Gynecology-Definitons-V2.pdf>. Retrieved September 23, 2019.
20. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. 2013. Washington, DC. Pages 451-459.
21. Chen, M., & Eugster, E. A. (2015). Central Precocious Puberty: Update on Diagnosis and Treatment. *Paediatric drugs*, 17(4), 273–281. <https://doi.org/10.1007/s40272-015-0130-8>
22. Chronic Pelvic Pain: ACOG Practice Bulletin, Number 218. *Obstet Gynecol.* 2020;135(3):e98-e109. doi:10.1097/AOG.0000000000003716. Accessed May 4, 2023.
23. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2023. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
24. Coleman, E, Radix, AE, Bouman WP, et al. "Standards of Care for the Health of Transgender and Gender Diverse People, Version 8." *International journal of transgender health* vol. 23,Suppl 1 S1-S259. 6 Sep. 2022, doi:10.1080/26895269.2022.2100644
25. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: May 4, 2023.
26. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
27. Eugster E. Treatment of Central Precocious Puberty. *Journal of the Endocrine Society.* 2019; 3(5): 965-972.
28. Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al.; Endocrine Society. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* 2009; 94(9):3132-3154.
29. Hembree WC, Cohen-Kettenis P, Gooren L, et al.; Endocrine Society. Endocrine Treatment of Gender Dysphoric/Gender Incongruent Persons. An Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* 2017; 102(11):1–35.
30. Kaplowitz P, Bloch C, the SECTION ON ENDOCRINOLOGY. Evaluation and Referral of Children With Signs of Early Puberty. *Pediatrics.* 2016;137(1):e20153732
31. Kletter GB, Klein KO, Wong YY. A pediatrician's guide to central precocious puberty. *Clin Pediatr.* 2015;54:414-424.
32. Lethaby A, Puscasiu L, Vollenhoven B. Preoperative medical therapy before surgery for uterine fibroids. *Cochrane Database Syst Rev.* 2017;11(11):CD000547. Published 2017 Nov 15. doi:10.1002/14651858.CD000547.pub2.
33. Lethaby A, Vollenhoven B, Sowter M. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. *Cochrane Database Syst Rev.* 2001; (2):CD000547.
34. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2023; Updated periodically.
35. Lupron Depot-Ped (leuprolide acetate for depot suspension) for intramuscular use [prescribing information]. North Chicago, IL. AbbVie, Inc.;May 2023.
36. Nebesio TD, Eugster EA. Current concepts in normal and abnormal puberty. *Curr Probl Pediatr Adolesc Health Care.* 2007;37(2):50–72. doi: 10.1016/j.cppeds.2006.10.005.
37. Römer, T. "Benefit of GnRH analogue pretreatment for hysteroscopic surgery in patients with bleeding disorders." *Gynecologic and obstetric investigation* vol. 45 Suppl 1 (1998): 12-20; discussion 21, 35. doi:10.1159/000052847.
38. Yan H, Shi J, Li X, et al. Oral gonadotropin-releasing hormone antagonists for treating endometriosis-associated pain: a systematic review and network meta-analysis. *Fertil Steril.* 2022;118(6):1102-1116. doi:10.1016/j.fertnstert.2022.08.856.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.